Key Points
- Director Jack Kaye sold 6,390 shares of uniQure on January 9 at an average price of $27.28 for $174,319, cutting his holding by 23.82% to 20,439 shares (approx. $557,576 after the sale); he also sold 38,810 shares on November 4 at ~$30.34.
- uniQure recently missed expectations, reporting Q3 EPS of -$1.38 vs. consensus -$0.85 and revenue of $3.7M vs. $4.46M, with very negative net margin and return on equity metrics.
- Analyst sentiment is mixed but tilted positive: ten Buys, two Holds and one Sell produce a "Moderate Buy" consensus and an average price target of $60.82, though individual targets and ratings vary widely.
uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Jack Kaye sold 6,390 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Jack Kaye also recently made the following trade(s):
- On Tuesday, November 4th, Jack Kaye sold 38,810 shares of uniQure stock. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40.
uniQure Stock Performance
NASDAQ:QURE opened at $23.04 on Tuesday. The business's fifty day moving average is $25.23 and its 200 day moving average is $27.68. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -5.25 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure N.V. has a 52-week low of $7.76 and a 52-week high of $71.50.
uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The company had revenue of $3.70 million for the quarter, compared to analysts' expectations of $4.46 million. Research analysts predict that uniQure N.V. will post -3.75 EPS for the current year.
Wall Street Analysts Forecast Growth
QURE has been the topic of several recent analyst reports. Leerink Partners lowered their target price on shares of uniQure from $68.00 to $60.00 and set an "outperform" rating on the stock in a research note on Monday, November 10th. Royal Bank Of Canada decreased their price target on shares of uniQure from $65.00 to $45.00 and set an "outperform" rating on the stock in a report on Monday, November 3rd. HC Wainwright dropped their price objective on uniQure from $110.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, November 4th. Weiss Ratings restated a "sell (d-)" rating on shares of uniQure in a research report on Wednesday, October 8th. Finally, UBS Group set a $95.00 price target on uniQure in a report on Thursday, September 25th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $60.82.
Get Our Latest Stock Report on uniQure
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in QURE. Jefferies Financial Group Inc. bought a new stake in uniQure during the second quarter worth about $29,217,000. JPMorgan Chase & Co. raised its holdings in shares of uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock valued at $25,199,000 after buying an additional 1,491,486 shares in the last quarter. Fred Alger Management LLC bought a new stake in uniQure in the 3rd quarter worth approximately $75,320,000. Sofinnova Investments Inc. boosted its stake in uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock worth $21,723,000 after buying an additional 1,012,585 shares in the last quarter. Finally, Avoro Capital Advisors LLC grew its position in uniQure by 22.6% during the third quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company's stock valued at $259,422,000 after acquiring an additional 819,444 shares during the last quarter. Institutional investors own 78.83% of the company's stock.
About uniQure
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
